Product Description
CNTX-6016 is a novel, potent and highly selective investigational cannabinoid 2 (CB2) agonist currently in Phase 1 clinical trials.
Mechanisms of Action: CB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Centrexion
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Chronic Pain|Nociceptive Pain|Pain Unspecified|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04857957 |
CNTX-6016o-HV/PDN-102 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2023-08-30 |
19% |
2023-11-02 |
|
NCT04154501 |
CNTX-6016o-HV-101 | P1 |
Completed |
Chronic Pain|Nociceptive Pain |
2019-08-21 |
2019-11-07 |